X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

On Manufacturing Day, a closer look at the biopharmaceutical sector’s contributions

By Megan Van Etten  |    October 4, 2019
Each year, the first Friday in October marks Manufacturing Day, an annual recognition of the critical role manufacturing-intensive industries play in powering innovation and generating jobs and...   Read More

The truth about the marketing and promotion of medicines

By Holly Campbell  |    October 3, 2019
Despite what critics say, the U.S. biopharmaceutical industry spends three times more on the research and development (R&D) of new treatments and cures than on the marketing and promotion of...   Read More

Survey shows out-of-pocket costs top health care concern for voters

By Holly Campbell  |    October 2, 2019
A recent national survey of 800 registered voters conducted by Public Opinion Strategies shows that health insurance premiums, deductibles and copays are the top health care concerns for...   Read More

By the Numbers: Pelosi’s radical plan puts America’s economy and jobs at risk

By Tom Wilbur  |    September 26, 2019
We already know that the radical drug pricing plan unveiled last week by House Speaker Nancy Pelosi is the wrong approach for patients, the U.S. health care system, and American innovation. But...   Read More

ICYMI: Fighting for a cure to ALS

By Anne McDonald Pritchett, PhD  |    September 25, 2019
Yesterday at The Atlantic Festival, I had the chance to speak with Amy, a biopharmaceutical researcher focused on amyotrophic lateral sclerosis (ALS). As a young girl, Amy’s father inspired her to...   Read More

Four reasons why the radical Pelosi Plan is the wrong approach

By Tom Wilbur  |    September 24, 2019
Speaker of the House Nancy Pelosi recently unveiled a radical plan that would restrict and fundamentally change how patients access medicines in the United States. It would threaten our country’s...   Read More

IP Explained: Will America Cede Global Medical Innovation Leadership to Asia?

By Megan Van Etten  |    September 18, 2019
Last month, Taiwan became the latest economy in Asia to take a bold step to bolster life sciences innovation and to accelerate economic growth. On August 20, 2019, Taiwan’s Food and Drug...   Read More

IP Explained: Four things to know about the Bayh-Dole Act

By Tom Wilbur  |    September 13, 2019
Thanks in large part to strong intellectual property protections – including policies that incentivize public and private investments in research and development (R&D) – the United States is the ...   Read More

Hospitals make 9 times more than physicians’ offices on provider-administered medicines

By Katie Koziara  |    September 10, 2019
A new study, conducted by the Partnership for Health Analytic Research (PHAR), found that hospitals retained 91% of the total profit on physician-administered medicines in the commercial market...   Read More

Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important

By Guest Contributor  |    September 4, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates